Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Codexis Stock a Buy?

TheMotleyFool

0 0

By digging through SEC filings of institutional shareholders, investors can unearth promising stocks hidden to most. Codexis (NASDAQ: CDXS) fits this bill. With a business focused on developing enzymes, Codexis has built a growing revenue stream through partnerships and licenses to its platform technology.

As of Sept. 30, institutional investors held over 86% of the outstanding shares. These include big names like BlackRock, Vanguard, and Fidelity as well as healthcare specialist funds including Vivo Ventures and Opaleye Management.

Source Fool.com

Like: 0

CDXS

Share